Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-019-02894-3
Abstract: BackgroundIn the phase 3 BFORE trial (NCT02130557), treatment with bosutinib resulted in a significantly higher major molecular response rate at 12 months versus imatinib in the modified intent-to-treat (mITT) population of patients with newly diagnosed chronic… read more here.
Keywords: phase; newly diagnosed; treatment; bfore trial ... See more keywords